Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosopatamab 225Ac - Dominari Holdings

Next Previous
Drug Profile

Rosopatamab 225Ac - Dominari Holdings

Alternative Names: 225Ac-J591; Ac-225 rosopatamab tetraxetan - Convergent Therapeutics; Actinium-225 radiolabeled J591; CONV 01-α; J591 - Dominari Holdings

Latest Information Update: 25 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Convergent Therapeutics; Weill Cornell Medicine
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 02 Jun 2026 Efficacy and adverse event data from a phase II CONVERGE-01 trial in Prostate cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology 9ASCO-2026)
  • 01 Jun 2026 Efficacy and adverse events data from the phase II CONVERGE-01 trial in metastatic castration-resistant Prostate cancer released by Convergent Therapeutics
  • 01 Jun 2026 Convergent Therapeutics plans a phase III trial for castration-resistant Prostate cancer (Metastatic disease, hormone refractory, Second-line therapy or greater) (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top